PIL in Supreme Court seeking cancellation of Ranbaxy licence
6 Jun 2013 12:02 AM GMT
An advocate on Wednesday approached the Supreme Court with a PIL seeking cancellation of the license granted to Ranbaxy Laboratories Ltd and for initiating probe against the pharma major for allegedly manufacturing and selling adulterated drugs.
The public interest litigation (PIL), which comes in the wake of the Indian pharma major being fined $500 million by the US Food and Drug Administration (USFDA) for making and selling ‘adulterated’ drugs, has also sought sealing of all its manufacturing units in India, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.
The PIL was mentioned before a bench of justices Gyan Sudha Misra and Madan B Lokur which asked the petitioner and advocate M L Sharma to complete the technical requirements with the registry before taking it on board for hearing.The bench said the PIL can be listed on the mentioning list for fixing the hearing next week.The petitioner has also sought a direction for prosecution of Ranbaxy’s current and former directors.
The public interest litigation (PIL), which comes in the wake of the Indian pharma major being fined $500 million by the US Food and Drug Administration (USFDA) for making and selling ‘adulterated’ drugs, has also sought sealing of all its manufacturing units in India, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.
The PIL was mentioned before a bench of justices Gyan Sudha Misra and Madan B Lokur which asked the petitioner and advocate M L Sharma to complete the technical requirements with the registry before taking it on board for hearing.The bench said the PIL can be listed on the mentioning list for fixing the hearing next week.The petitioner has also sought a direction for prosecution of Ranbaxy’s current and former directors.
Next Story
